Lantheus Holdings, Inc. LNTH
We are the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes. We classify our products into three product categories: Radiopharmaceutical Oncology, Precision Diagnostics, and Strategic Partnerships and Other Revenue. Our Radiopharmaceutical Oncology product helps healthcare professionals ("HCPs") Find, Fight and Follow cancer. Our Precision Diagnostic products assist HCPs to Find and Follow diseases. Our Strategic Partnerships include biomarkers and digital solutions in support of our partners' therapeutic development, out-licensing agreements for non-core assets and optimization of our assets geographically, and contract development and manufacturing organization ("CDMO") revenue generated by Evergreen.
Valuation FY2025 figures against the last close
Where the revenue comes from as reported in the latest 10-K
Revenue by geography
- United States
- Rest of world
| Region | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| United States | $1.46B | $1.48B | $1.26B |
| Rest of world | $82.7M | $49.2M | $34.3M |
As the company reported it, from the “Revenue from Contracts with Customers - Schedule of Revenue by Geographic Region Determined by Location of Customer or Other Party (Details)” note of its latest 10-K. Every figure here has been checked against the total revenue the same filing reported. Regions are the filer's own and are not mapped onto a standard list — one company's “Americas” and another's “United States” are different areas, and making them look comparable would mean making at least one of them wrong. Slices under 1% are folded into “Other”.
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.54B | $1.53B | $1.30B | $935.1M | $425.2M | $339.4M | $347.3M | $343.4M | $331.4M | $301.9M |
| Cost of revenue | $599.7M | $545.6M | $586.9M | $353.4M | $237.5M | $200.6M | $172.5M | $168.5M | $169.2M | $164.1M |
| Gross profit | $942.0M | $988.3M | $709.5M | $581.7M | $187.7M | $138.8M | $174.8M | $174.9M | $162.1M | $137.8M |
| R&D | $177.3M | $168.1M | $77.7M | $311.7M | $45.0M | $32.8M | $20.0M | $17.1M | $18.1M | $12.2M |
| SG&A | $275.1M | $193.7M | $125.5M | $133.6M | $150.4M | $69.3M | $61.2M | $50.2M | $49.8M | $38.8M |
| Total operating expenses | — | — | — | — | — | $143.0M | $123.2M | $110.4M | $110.3M | — |
| Operating income | $310.8M | $457.0M | $364.6M | $36.2M | -$60.8M | -$4.2M | $51.7M | $64.5M | $51.9M | $56.6M |
| Interest expense | $19.7M | $19.7M | $20.0M | $7.2M | $7.8M | $9.5M | $13.6M | $17.4M | $18.4M | $26.6M |
| Pre-tax income | $313.8M | $431.0M | $410.9M | $26.7M | -$75.0M | -$11.5M | $28.6M | $49.5M | $39.6M | $28.3M |
| Income tax | $80.2M | $118.5M | $84.3M | $1.3M | $3.8M | $2.0M | $3.0M | $9.0M | $83.7M | $1.5M |
| Net income | $233.6M | $312.4M | $326.7M | $28.1M | -$71.3M | -$13.5M | $31.7M | $40.5M | $123.4M | — |
| EPS, basic | 3.46 | 4.52 | 4.79 | 0.41 | -1.06 | -0.25 | 0.81 | 1.06 | 3.31 | 0.84 |
| EPS, diluted | 3.41 | 4.36 | 4.65 | 0.40 | -1.06 | -0.25 | 0.79 | 1.03 | 3.17 | 0.82 |
| Shares, diluted (wtd. avg.) | 68.4M | 71.7M | 70.2M | 70.7M | 67.5M | 54.1M | 40.1M | 39.5M | 38.9M | 32.7M |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $359.1M | $912.8M | $713.7M | $417.2M | $100.7M | $82.7M | $92.9M | $113.4M | $76.3M | $51.2M |
| Receivables | $358.6M | $321.3M | $284.3M | $213.4M | $89.3M | $54.0M | $43.5M | $43.8M | $40.3M | $36.8M |
| Inventory | $64.7M | $68.0M | $64.0M | $35.5M | $35.1M | $35.7M | $29.2M | $33.0M | $26.1M | $17.6M |
| Total current assets | $900.0M | $1.33B | $1.09B | $677.6M | $235.8M | $184.2M | $172.9M | $195.4M | $147.8M | $110.8M |
| Property, plant and equipment | $163.7M | $176.8M | $146.7M | $122.2M | $116.8M | $120.2M | $116.5M | $107.9M | $93.0M | $94.2M |
| Goodwill | $239.5M | $61.2M | $61.2M | $61.2M | $61.2M | $58.6M | $15.7M | $15.7M | $15.7M | $15.7M |
| Other intangibles | $722.8M | $161.8M | $152.0M | $315.3M | $348.5M | $376.0M | $7.3M | $9.1M | $11.8M | $15.1M |
| Total assets | $2.23B | $1.98B | $1.65B | $1.32B | $863.8M | $869.8M | $405.9M | $439.8M | $383.9M | $255.9M |
| Accounts payable | $42.9M | $34.6M | $41.2M | $20.6M | $20.8M | $16.3M | $18.6M | $18.0M | $17.5M | $18.9M |
| Short-term debt | $738.0K | $974.0K | $823.0K | $354.0K | $11.6M | $20.7M | $10.1M | $2.8M | $2.8M | $3.6M |
| Total current liabilities | $333.4M | $240.5M | $187.3M | $247.7M | $90.5M | $80.5M | $66.1M | $52.8M | $46.8M | $43.8M |
| Long-term debt | — | — | — | $557.7M | $163.1M | $197.7M | $183.9M | $263.7M | $265.4M | $274.5M |
| Total liabilities | $1.14B | $892.3M | $835.3M | $874.1M | $399.3M | $355.6M | $291.3M | $368.8M | $360.6M | $362.4M |
| Retained earnings | $679.5M | $445.9M | $133.5M | -$193.2M | -$221.2M | -$149.9M | -$136.5M | -$168.1M | -$209.0M | -$332.4M |
| Total equity | $1.09B | $1.09B | $815.9M | $447.1M | $464.4M | $514.2M | $114.6M | $71.0M | $23.3M | -$106.5M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $390.1M | $544.8M | $305.3M | $281.8M | $53.9M | $16.4M | $80.4M | $61.2M | $54.8M | $49.6M |
| Depreciation and amortisation | $70.1M | $64.6M | $60.0M | $47.9M | $42.3M | $24.7M | $13.4M | $13.9M | $19.2M | $18.3M |
| Stock-based compensation | $85.6M | $76.4M | $50.5M | $29.3M | $15.9M | $14.1M | $12.5M | $8.7M | $5.9M | $2.5M |
| Capital expenditure | $36.1M | $51.6M | $46.6M | $18.3M | $0 | $0 | $22.1M | $20.1M | $17.5M | $7.4M |
| Investing cash flow | -$627.2M | -$226.0M | $5.9M | -$276.5M | $3.7M | -$4.9M | -$22.1M | -$19.1M | -$16.3M | $3.3M |
| Financing cash flow | -$316.6M | -$118.5M | -$13.1M | $311.7M | -$39.3M | -$21.9M | -$78.9M | -$4.7M | -$13.4M | -$30.2M |
| Buybacks | $300.0M | $100.0M | $0 | $75.0M | $0 | $0 | — | — | — | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001193125-26-073498.
Plot the figures US dollars
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $301.9M | $331.4M | $343.4M | $347.3M | $339.4M | $425.2M | $935.1M | $1.30B | $1.53B | $1.54B |
| Gross profit | $137.8M | $162.1M | $174.9M | $174.8M | $138.8M | $187.7M | $581.7M | $709.5M | $988.3M | $942.0M |
| Net income | — | $123.4M | $40.5M | $31.7M | -$13.5M | -$71.3M | $28.1M | $326.7M | $312.4M | $233.6M |
Recent filings and events
- Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
- Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
- Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
- Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
- Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
- Results announced Item 2.02
- Shareholder rights changed The terms attaching to the shares themselves have changed. Item 3.03
- Officer or director change Item 5.02
- Charter or fiscal year changed A change to the company's governing documents, or to when its year ends. Item 5.03
- Shareholder vote The results of the annual meeting or a special vote. Item 5.07
- Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
- Results announced Item 2.02
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 2835
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| IDXX | IDEXX LABORATORIES INC /DE | $44.15B | 42.8x | 10.4% |
| NEOG | NEOGEN CORP | $2.66B | — | -2.7% |
| CLDX | Celldex Therapeutics, Inc. | $2.30B | — | -78.0% |
| NTLA | Intellia Therapeutics, Inc. | $1.57B | — | 16.9% |
| QDEL | QuidelOrtho Corp | $941.5M | — | -1.9% |
| ACHV | ACHIEVE LIFE SCIENCES, INC. | $667.8M | — | — |
| MYGN | MYRIAD GENETICS INC | $556.7M | — | -1.6% |
| TKNO | Alpha Teknova, Inc. | $344.7M | — | 7.4% |